Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer.

Current cancer drug targets - 1 Aug 2008

Cortinovis D L, Andriani F, Livio A, Fabbri A, Perrone F, Marcomini B, Pilotti S, Mariani L, Bidoli P, Bajetta E, Roz L, Sozzi G

Abstract excerpt

Inactivation of the FHIT and TP53 genes is frequently observed in primary non-small cell lung cancers (NSCLC) and cell lines and may contribute to resistance to apoptotic stimuli elicited by various anti-tumor drugs. To evaluate a possible relationship between FHIT and TP53 status and response to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acid Anhydride Hydrolases
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carboplatin

Share to Deoxycytidine

Share to Gemcitabine

Share to Immunoenzyme Techniques

Share to Neoplasm Staging

Share to Survival Rate

Source

Identifiers

PMID: 18690840
DOI: 10.2174/156800908785133204

Genes

FHIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-18690840-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer.PMID 18690840Read ↗

Utilizing TP53 hotspot mutations as effective predictors of gemcitabine treatment outcome in non-small-cell lung cancerSemantic proximity Read ↗

Synergistic Tumor Suppression by Coexpression of FHIT and p53 Coincides with FHIT-Mediated MDM2 Inactivation and p53 Stabilization in Human Non-Small Cell Lung Cancer CellsSemantic proximity Read ↗

Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK‐rearranged non‐small‐cell lung cancerSemantic proximity Read ↗

Aberration of FHIT gene is associated with increased tumor proliferation and decreased apoptosis-clinical evidence in lung and head and neck carcinomas.Semantic proximity Read ↗

Molecular genetic alterations of FHIT and p53 genes in benign and malignant thyroid gland lesions.Semantic proximity Read ↗

Gene mutations and polymorphisms of TP53 and FHIT in chronic esophagitis and esophageal carcinoma.Semantic proximity Read ↗

p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer.Semantic proximity Read ↗

The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-based neoadjuvant therapy in stage III non-small cell lung cancer.Semantic proximity Read ↗

[Association of the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy with p53 and p73 polymorphisms].Semantic proximity Read ↗

[Effects of ectogenous FHIT gene on reversing malignant phenotype of human lung adenocarcinoma cells A549].Semantic proximity Read ↗

Restoration of fragile histidine triad ( <i>FHIT</i> ) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell linesSemantic proximity Read ↗

Tumor suppressor Fhit protein interacts with protoporphyrin IX in vitro and enhances the response of HeLa cells to photodynamic therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.